Results 51 to 60 of about 147,286 (225)

Co-infection of Leishmania infantum and a Crithidia-related species in a case of refractory relapsed visceral leishmaniasis with non-ulcerated cutaneous manifestation in Brazil

open access: yesInternational Journal of Infectious Diseases, 2023
We report a refractory and relapsed visceral leishmaniasis case in a male child patient followed from 2016 to 2020, whose clinical isolates from multiple relapses were analyzed at the genome level.
Luana Aparecida Rogerio   +12 more
doaj   +1 more source

Age-related alteration of arginase activity impacts on severity of leishmaniasis. [PDF]

open access: yes, 2008
BACKGROUND: The leishmaniases are a group of vector-borne parasitic diseases that represent a major international public health problem; they belong to the most neglected tropical diseases and have one of the highest rates of morbidity and mortality. The
Asrat Hailu   +40 more
core   +2 more sources

Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report

open access: yesRevista da Sociedade Brasileira de Medicina Tropical
Visceral leishmaniasis is common in Brazil and is caused by Leishmania (Leishmania) infantum/chagasi. Post-kala-azar dermal leishmaniasis frequently follows visceral leishmaniasis caused by L.
José Angelo Lauletta Lindoso   +5 more
doaj   +1 more source

Acute liver failure due to visceral leishmaniasis in Barcelona: a case report

open access: yesBMC Infectious Diseases, 2019
Background Leishmaniasis is an emerging infectious disease. Due to human migration and tourism, visceral leishmaniasis may become more common in non-endemic areas. In the Mediterranean basin, visceral leishmaniasis typically occurs in rural regions. Case
Iratxe Martinez de Narvajas   +10 more
doaj   +1 more source

Structures, targets and recent approaches in anti-leishmanial drug discovery and development. [PDF]

open access: yes, 2011
Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002.
Karin Seifert, Seifert, Karin
core   +1 more source

Systemic treatment of cutaneous leishmaniasis: A systematic review and meta‐analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This systematic review and meta‐analysis assessed systemic treatments for cutaneous leishmaniasis across 83 studies and 4603 patients. Treatment efficacies of meglumine antimoniate, miltefosine, azoles, pentamidine, and liposomal amphotericin B varied by region and species. Miltefosine showed consistent evidence across multiple settings.
Maximilian Egg   +10 more
wiley   +1 more source

TLR4 and TLR9 polymorphism: Probable role in susceptibility among the population of Bihar for Indian visceral leishmaniasis

open access: yesInnate Immunity, 2021
Genetic variations in the host TLRs genes play an important role in susceptibility and/or resistance to visceral leishmaniasis by altering the host-pathogen interaction.
Abhishek Mandal   +5 more
doaj   +1 more source

Precursor‐targeted immune‐mediated anaemia in a dog with concurrent haemoparasite seroreactivity: Diagnostic challenges and therapeutic response

open access: yesVeterinary Record Case Reports, Volume 14, Issue 4, November 2026.
Summary Precursor‐targeted immune‐mediated anaemia (PIMA) is an increasingly recognised cause of nonregenerative anaemia in dogs and may be difficult to distinguish from infectious or other immune‐mediated conditions. This report describes a dog presenting severe nonregenerative anaemia, leukopenia and thrombocytopenia, initially testing seroreactive ...
Vinícius dos Santos Resende Rodrigues   +5 more
wiley   +1 more source

Clinical Impact of Haemophagocytic Lymphohistiocytosis Among Patients With HIV/AIDS and Disseminated Histoplasmosis in a Hyperendemic Region of Northeastern Brazil

open access: yesMycoses, Volume 69, Issue 11, November 2026.
ABSTRACT Background Haemophagocytic lymphohistiocytosis (HLH) is a life‐threatening hyperinflammatory syndrome that may occur in people living with HIV/AIDS (PLWHA), often triggered by opportunistic infections such as disseminated histoplasmosis (DH).
Matheus Alves de Lima Mota   +9 more
wiley   +1 more source

Treatment of Visceral Leishmaniasis

open access: yesArchives of Pediatrics & Adolescent Medicine, 1992
Sir .—Mahieu and Van Acker 1 reported a case of visceral leishmaniasis (kalaazar) in the November 1991 issue of AJDC . Several case reports were included in the references, but only a few were from Mediterranean countries in which the disease is more prevalent, as mentioned by the authors. I would like to bring our experience with this disease into the
openaire   +3 more sources

Home - About - Disclaimer - Privacy